CYSLTR1 and COVID-19: Another approach to the treatment of COVID-19, based on the use of the cysteinyl leukotriene receptor 1 (CysLT1) antagonist Montelukast, was recently proposed (https://clinicaltrials.gov/ct2/show/NCT04389411).